Home » Newsletters » BioWorld

BioWorld

Feb. 20, 1992

View Archived Issues

EPITOPE TOLD TO EXPAND DISEASE TARGETS

SANDOZ COMPLETES SYSTEMIX TENDER OFFER

TAXOL MAKER CLOSES PRIVATE PLACEMENT

PARKINSON'S TREATMENT DISAPPOINTING

ENDOTHELIN STRUCTURE DESCRIBED

INNOVET TO ACQUIRE COLLABORATOR

SYNTRO-HOECHST ANIMAL VACCINE DEAL

IVAX UNIT BEGINS ALZHEIMER'S TRIALS

CHIMP STILL FREE OF AIDS INFECTION

WALL ST. VENTS FRUSTRATION AT CENTOCOR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...